Clinical review report: Buprenorphine extended-release injection (Sublocade) (Indivior Canada, Ltd.) indication : for the management of moderate-to-severe opioid use disorder in adult patients who have been inducted and clinically stabilized on a transmucosal buprenorphine-containing product
The objective of this report was to perform a systematic review of the beneficial and harmful effects of buprenorphine extended-release injection (BUP-ER) 100 mg and 300 mg for the management of moderate-to-severe opioid use disorder in adult patients who have been inducted and clinically stabilized...
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
July 2019, 2019
|
Edition: | Version: final |
Series: | CADTH common drug review
|
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references